Morgan Stanley analyst Keith Weiss maintains Splunk (NASDAQ:SPLK) with a Equal-Weight and lowers the price target from $123 to $110.
AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase II Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer
